A brand-name pharmaceutical company engaged in patent litigation with a generic competitor settles the dispute by paying the generic competitor a significant sum of money to drop the litigation and stay out of the market until sometime before the brand-name's patents expire. Because the patent holder is the party paying, rather than the other way around, this type of agreement is called a 'reverse-payment.' It's an intellectual property strategy we're seeing more and more often within the pharmaceutical industry - at least, we were, until a recent Supreme Court decision.
This resource is only available to our paid members. You can Join Us or Sign in to get access to this resource.